How Mibolerone Affects c-myc in Prostate Cancer Cells
Author Information
Author(s): D.A. Wolf, F. Kohlhuber, P. Schulz, F. Fittler, D. Eick
Primary Institution: Institut für Physiologische Chemie der Universität München
Hypothesis
The synthetic androgen mibolerone down-regulates c-myc RNA in human prostate carcinoma cells.
Conclusion
Mibolerone reduces c-myc RNA levels in LNCaP cells by inhibiting transcription initiation.
Supporting Evidence
- Mibolerone treatment leads to a significant decrease in c-myc RNA levels after 12-72 hours.
- The effect of mibolerone on c-myc RNA levels is reversible upon hormone withdrawal.
- Excess antiandrogen can counteract the down-regulation of c-myc by mibolerone.
Takeaway
Mibolerone is a synthetic hormone that helps stop cancer cells from growing by lowering the levels of a specific gene called c-myc.
Methodology
LNCaP prostate carcinoma cells were treated with mibolerone, and c-myc RNA levels were analyzed using Northern blotting and nuclear run-on assays.
Limitations
The study primarily focuses on a single cell line, which may not represent all prostate cancer types.
Want to read the original?
Access the complete publication on the publisher's website